Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895912 | 0.85 | ALDH1A1 (0.65) | ALDH1A1HTTLMNAMAPTMAPK1 | |
| SCHEMBL6323058 | 0.81 | NPC1 (0.51) | ALDH1A1HTTLMNAMAPTMAPK1 | |
| SCHEMBL4896863 | 0.79 | ALDH1A1 (0.69) | ALDH1A1HTTLMNAMAPTMAPK1 | |
| SCHEMBL4896955 | 0.77 | ALDH1A1 (0.67) | ALDH1A1HTTLMNAMAPTMAPK1 | |
| SCHEMBL30715120 | 0.77 | ALDH1A1 (0.65) | ALDH1A1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL29195048 | 0.77 | ALDH1A1 (0.65) | ALDH1A1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL29195059 | 0.76 | S1PR4 (0.60) | ALDH1A1HTTLMNAMAPTRAB9A | |
| SCHEMBL4897438 | 0.75 | ALDH1A1 (0.64) | ALDH1A1HTTLMNAMAPTMAPK1 | |
| SCHEMBL4945600 | 0.74 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL6427592 | 0.74 | HPGD (0.68) | ALDH1A1HTTLMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | ALDH1A1 3961/4885HTT 2077/4885LMNA 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.